The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Wild, “ delivery of Covidity by inhalation “
That would be fantastic. I would be still keen to see delivery via injection, and proven up while alternatives are evaluated hopefully in parallel. Time is of the essence
Take care
Hi Ivy, you say “the technical benefits of SN15 consider that the DNA plasmid is relatively easy to scale up and cheap to manufacture which again are very attractive attributes..”
You are absolutely correct. We just need to complete a Ph1 with a approved delivery mechanism then we will start the process of recognition. Come on CH we need to have a time line you can deliver on and the race has started
The CEPI article dated 1/3/2021 says “For example, scientists at the University of Nottingham in the UK are working alongside pharmaceutical company Scancell and Nottingham Trent University to test its COVID-19 vaccine candidate, SN14, which targets both the spike protein as well as the nucleocapsid, or N-protein. By targeting this additional viral structure, which is far less likely to mutate, the vaccine if found safe and effective could work to protect people against COVID-19 irrespective of any mutations to the spike protein and, in theory, could work across other coronaviruses.”
Can we confirm SN14, is now superseded by SN15 and if so, is it being or had been manufactured for P1 trials?
Has the delivery mechanism now been approved ?
Message to inspire new investor to the fact we have Covidity for C19 and loads of other advanced products in cancer vaccines
May have been the desired objective
However, the overly technical presentation would have done nothing to excited investors hoping for news of a second generation vaccine.
Cliff the most boring presenter, needed to delivery a positive update told in simple English so new investors knew what a fantastic scientific organisation they had invested in. Suggest Lindy does a simple presentations on what these new vaccines will do for cancer sufferers in her enthusiastic stile and let Cliff do the slipping start date ( I though Q1 then Q2 2021 now looks like 2022 )
We may imagine that Professor Van Tam has mentioned The work that UON are doing with Scancell to develop a second generation vaccine and is showing great promise also how alternate delivery mechanisms may eventually solve the way to deliver via posting oral vaccines to 60 million people may be possible in the not to distant future.
That may get Boris attention
Similar to COVID-19 vaccines, Chinese scientists have developed a new mRNA vaccine that activates the immune system to attack a protein made by tumour cells instead of the protein produced by the coronavirus.
Crucially, this mRNA is contained in a breakthrough hydrogel developed by the team from the Chinese National Centre for Nanoscience and Technology, that, when injected into mice with melanoma, slowly released the RNA which successfully caused tumours to shrink and prevented them from metastasising.
Both of the COVID-19 vaccines developed by Pfizer/BioNTech and Moderna use mRNA to send genetic instructions to the body's cells that result in them producing antibodies for the coronavirus without the virus actually being introduced to their body.
The mRNA cancer treatment, reported in the American Chemical Society's Nano Letters, works in a similar way - by entering antigen-presenting cells and making the tumour protein, triggering other immune cells to seek and destroy real tumour cells that also make this protein.
Do we need to be concerned ?
I think we all have been waiting for Redmile to fly in a capable CEO that can shake up the commercial aspect of this great scientific organisation. I remember when he arrive he said “we need to get into trial and gather data”
Several Covid vaccines now available and bought to market with more to follow Scancell are still without a delivery device.
And when will we start a Phase 1 trial
We need a can do leadership
No excuses
Time will tell
“Rob Naylor, incoming CEO
The Company is a newly established investing company, seeking to provide investors with exposure to a portfolio concentrating on fast-growing and/or high potential Life Sciences businesses operating predominantly in the UK, continental Europe and the US, utilising the Board's experience and in particular that of the Chairman, David Evans, to seek to generate capital growth over the long term for shareholders.”
Could be good for Scancell if they take a position
Wild
“Scancell have chosen their targets with much planning and forethought in my opinion “
You are right Science and Planning have been their strong point getting into test/ clinical trial have alluded them for 5 Years. As a fellow LTH I feel time is of the essence. So many bio’s being bought out by the big boys and so much exiting progress in immunology I hope they can wait for us to plan and deliver. Just lucky Redmile didn’t invest when we all saw the light years ago.
“Carpe diem”
Chester
This looks like the question many of us are looking to be answered
I would like you to use this as a start which could be added to or amended so we can post prior the AGM to give the board a chance to provide the best answers after proper consideration
Max